获取途径

作者

Yanlin Li Xiaohui Jia Yonghao Du Ziyang Mao Yajuan Zhang Yuan Shen Hong Sun Mengjie Liu Gang Niu Jun Wang Jie Hu Min Jiao Hui Guo

作者单位

¹Department of Medical Oncology, First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China ⁵Suzhou DiYinAn Biotech Co., Ltd., Suzhou, China ⁴Department of Oncology, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Jinan, China ⁷Bioinspired Engineering and Biomechanics Center, Xi’an Jiaotong University, Ministry of Education of China, Xi’an, China ³Department of Epidemiology and Biostatistics, School of Public Health, Xi’an Jiaotong University Health Science Center, Xi’an, China ²Department of Radiology, First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China ⁶Key Laboratory of Environment and Genes Related to Diseases, Xi’an Jiaotong University, Ministry of Education of China, Xi’an, China

刊名

Frontiers in Oncology

年份

2022

卷号

Vol.12

关键词

eosinophil percentage checkpoint inhibitor pneumonitis immunotherapy lung cancer biomarker

摘要

IntroductionCheckpoint inhibitor pneumonitis is a common serious adverse event caused by immune checkpoint inhibitors , and severe CIP can be life-threatening. We aimed to investigate the role of peripheral blood cells in diagnosis, prediction, and prognosis evaluation for all and severe CIP.Materials and methodsPatients with lung cancer receiving ICIs were enrolled in this retrospective study. Baseline was defined as the time of ICI initiation, endpoint was defined as the time of clinical diag...更多

IntroductionCheckpoint inhibitor pneumonitis is a common serious adverse event caused by immune checkpoint inhibitors , and severe CIP can be life-threatening. We aimed to investigate the role of peripheral blood cells in diagnosis, prediction, and prognosis evaluation for all and severe CIP.Materials and methodsPatients with lung cancer receiving ICIs were enrolled in this retrospective study. Baseline was defined as the time of ICI initiation, endpoint was defined as the time of clinical diagnosis of CIP or the last ICI treatment, and follow-up point was defined as 1 week after CIP. Eosinophil percentages at baseline, endpoint, and follow-up point were shortened to “Ebas”, “Eend and “Efol”, respectively.ResultsAmong 430 patients included, the incidence of CIP was 15.6%, and severe CIP was 3.7%. The Eend/Ebas value was lower in patients with CIP , especially severe CIP . Receiver operating characteristic curves revealed that Eend/Ebas could serve as a biomarker to diagnose CIP and severe CIP . For severe CIP, the eosinophil percentage declined before the symptoms appeared and CT diagnosis. The eosinophil percentage significantly elevated at the follow-up point in the recovery group but not in the non-recovery group. The CIP patients with Efol/Ebas ≥1.0 had significantly prolonged overall survival and after-CIP survival . The same results were found in severe CIP but without a statistical difference.ConclusionsEosinophil percentage was associated with the diagnosis, prediction, and prognosis of CIP and severe CIP.收起

文献类型

期刊